Pilot Evaluation of The Effect of Anti-nerve Growth Factor Antibody on Sensory System Function in Dogs with Degenerative Joint Disease-Associated Pain

2018 ◽  
Author(s):  
D. Knazovicky ◽  
M. Freire ◽  
B. Case ◽  
D. Gearing ◽  
B. Lascelles
Keyword(s):  
Nerve Growth Factor ◽  
Growth Factor ◽  
Sensory System ◽  
Degenerative Joint Disease ◽  
Joint Disease ◽  
System Function ◽  
Nerve Growth

scholarly journals Efficacy and Safety of an Anti-nerve Growth Factor Antibody (Frunevetmab) for the Treatment of Degenerative Joint Disease-Associated Chronic Pain in Cats: A Multisite Pilot Field Study

2021 ◽  
Vol 8 ◽  
Author(s):  
Margaret E. Gruen ◽  
Jamie A. E. Myers ◽  
B. Duncan X. Lascelles
Keyword(s):  
Chronic Pain ◽  
Nerve Growth Factor ◽  
Pain Management ◽  
Growth Factor ◽  
Unmet Need ◽  
Degenerative Joint Disease ◽  
Joint Disease ◽  
Efficacy And Safety ◽  
Nerve Growth ◽  
Objectively Measured

Background: Pain management for cats with degenerative joint disease (DJD) remains a critical unmet need. Recent work has shown promise for a feline-specific anti-nerve growth factor monoclonal antibody (frunevetmab) to deliver safe and effective pain management. Our objectives were to evaluate the efficacy and safety of frunevetmab administered twice using two administration routes (subcutaneous and intravenous) compared to placebo.Methods: This was a randomized placebo-controlled, double-masked study. After a week-long pain and activity baseline, 126 cats were randomized to receive injections of frunevetmab (IV then SC; n = 42 or SC then SC; n = 43) or placebo (IV then SC; n = 41) on Days 0 and 28. Owners completed questionnaires on Days 14, 28, 42, and 56. Accelerometry data were collected continuously throughout.Results: Owner questionnaire results showed significant improvement in frunevetmab-treated cats [compared to placebo; (p < 0.05)] at Days 42 and 56; no difference was found between routes of administration for frunevetmab. All groups had decreased objectively measured weekly activity from baseline; frunevetmab-treated cats had a mean decrease of 0.9%, while placebo-treated cats had a mean decrease of 9.3%. Treatments were generally well-tolerated. The majority of adverse events included dermatitis/alopecia related to activity-monitor collars; these occurred in a higher percentage of frunevetmab, compared to placebo, treated cats.Conclusions and Clinical Relevance: Treatment with frunevetmab provided improvements in owner ratings of mobility over treatment with placebo; these results were supported by objectively measured accelerometry. Frunevetmab has the potential to address a critical gap in the treatment of chronic pain in cats.

Screening Natural Products for Effects on Nerve Growth Factor (NGF) Stimulated Neuritogenesis and Neuritic Outgrowth

Planta Medica ◽  
2011 ◽  
Vol 77 (05) ◽  
Author(s):  
ND Chaurasiya ◽  
R Sahu ◽  
V Samoylenko ◽  
M Ilias ◽  
LA Walker ◽  
...  
Keyword(s):  
Natural Products ◽  
Nerve Growth Factor ◽  
Growth Factor ◽  
Nerve Growth ◽  
Neuritic Outgrowth

Nerve Growth Factor overexpression in Clara cells suppresses metastasis and tumor growth in a mouse model of experimental lung metastasis

Pneumologie ◽  
2012 ◽  
Vol 66 (06) ◽  
Author(s):  
K Seidler ◽  
A Sydykov ◽  
S Müller-Brüsselbach ◽  
R Müller ◽  
N Weißmann ◽  
...  
Keyword(s):  
Nerve Growth Factor ◽  
Growth Factor ◽  
Mouse Model ◽  
Tumor Growth ◽  
Lung Metastasis ◽  
Clara Cells ◽  
Nerve Growth

Degenerating and Painful Human Intervertebral Discs Release Pronociceptive Factors and Increase Neurite Sprouting and CGRP via Nerve Growth Factor

2014 ◽  
Vol 4 (1_suppl) ◽  
pp. s-0034-1376539-s-0034-1376539
Author(s):  
E. Krock ◽  
D. H. Rosenzweig ◽  
A. J. Chabot-Dore ◽  
P. Jarzem ◽  
M. H. Weber ◽  
...  
Keyword(s):  
Nerve Growth Factor ◽  
Growth Factor ◽  
Intervertebral Discs ◽  
Nerve Growth
Sign in / Sign up

Export Citation Format

Share Document